Market Cap: $24.45M
AI
Atossa Therapeutics, Inc.
ATOS
NASDAQ (NASDAQ Capital Market)USD
Market Cap: $24.45M
Atossa Therapeutics (Ticker: ATOS) successfully finalizes a registered direct offering, generating approximately $4.5 million. This funding is crucial as the company progresses its clinical efforts ai…
Atossa Therapeutics, Inc. has announced a registered direct offering aimed at raising up to $16.5 million in gross proceeds, which will primarily support its clinical development efforts in oncology.…
Atossa Therapeutics (Ticker: ATOS) announces significant advancements in breast cancer treatment with two abstracts accepted for presentation at the ASCO 2026 Annual Meeting. The focus is on the effic…
Atossa Therapeutics, Inc. unveils significant findings from the Phase 2 KARISMA Endoxifen trial, aligning with its commitment to developing innovative treatments for breast cancer. The trial, which in…
Atossa Therapeutics Enhances Clinical Leadership to Advance Targeted Therapies Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical firm renowned for developing innovative treatments for onco…
Atossa Therapeutics Expands Hope for Duchenne Muscular Dystrophy with (Z)-Endoxifen Atossa Therapeutics, Inc. recently garners attention in the biopharmaceutical sector with its presentation at the MD…
Atossa Therapeutics Advances Promising DMD Therapy Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, showcases significant advancements in its investigational therapy, (Z)-endoxif…
Promising Advances in DMD Treatment: Atossa Therapeutics' (Z)-endoxifen Shows Potential Atossa Therapeutics, Inc. presents exciting findings regarding its investigational therapy, (Z)-endoxifen, at th…
Congress reauthorization preserves voucher path for Atossa's DMD candidate Atossa Therapeutics says a five‑year reauthorization of the Rare Pediatric Disease (RPD) Priority Review Voucher (PRV) Progra…
Congressional PRV extension underpins Atossa’s DMD program WASHINGTON — Congress passes a five-year reauthorization of the Rare Pediatric Disease Priority Review Voucher (PRV) program, a move that pre…
Atossa Therapeutics Advances Rare Disease Treatment with FDA Designation Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on innovative therapies for oncology and urgent m…
Atossa Therapeutics Advances Cancer Treatment with FDA Approval for (Z)-endoxifen Study Atossa Therapeutics, Inc. has reached a pivotal regulatory milestone with the U.S. Food and Drug Administration…
Atossa Therapeutics Advances DMD Treatment with FDA Designation Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, achieves a significant milestone by receiving Rare Pediatric Dise…
Atossa Therapeutics Strengthens Patent Portfolio for Endoxifen in Breast Cancer Treatment Atossa Therapeutics, Inc. announces a significant advancement in its intellectual property landscape with the…
Atossa Therapeutics Secures New Patent for (Z)-Endoxifen, Enhancing Cancer Treatment Prospects Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to innovative therapies f…
Atossa Therapeutics Advances Breast Cancer Strategies Following FDA Meeting Atossa Therapeutics, Inc. continues to forge ahead in the realm of breast cancer treatment and prevention, bolstered by rece…
Atossa Therapeutics Advances Breast Cancer Treatment with FDA Insights Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in innovative breast cancer therapies, achieve…
Atossa Therapeutics Explores New Horizons in Duchenne Muscular Dystrophy Treatment Atossa Therapeutics, Inc. recently publishes a peer-reviewed article that delves into its investigational therapy, (Z…
Atossa Therapeutics Advances Research on (Z)-endoxifen for Duchenne Muscular Dystrophy Atossa Therapeutics, Inc. has made a significant contribution to the field of neuromuscular disease treatment wit…
Atossa Therapeutics Engages Investors at Maxim Growth Summit Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, actively seeks new investors by participating in the upcoming Maxim…
Atossa Therapeutics Strengthens Financial Leadership with New CFO Appointment Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to advancing breast cancer treatment and p…
Atossa Therapeutics Strengthens Intellectual Property for Z-Endoxifen Atossa Therapeutics, Inc. makes notable advancements in its intellectual property strategy for Z-endoxifen, a critical component i…
Atossa Therapeutics Strengthens Intellectual Property for Z-Endoxifen Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to advancing breast cancer treatment and preventio…
Atossa Therapeutics Refines Clinical Trial for Breast Cancer Treatment Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in innovative therapies for breast cancer, ann…
Atossa Therapeutics Optimizes EVANGELINE Study to Enhance Efficiency in Breast Cancer Treatment Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to innovative breast can…